Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H21N3O3 |
Molecular Weight | 363.4097 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC1=C(C)C=C(C=N1)C2=C(C)C3=C(C=C2)C(=O)C(=CN3C4CC4)C(O)=O
InChI
InChIKey=XPIJWUTXQAGSLK-UHFFFAOYSA-N
InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)
Molecular Formula | C21H21N3O3 |
Molecular Weight | 363.4097 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25340832Curator's Comment: description was created based on several sources, including
https://www.drugs.com/history/ozenoxacin.html | https://clinicaltrials.gov/ct2/show/NCT02090764 | https://www.ncbi.nlm.nih.gov/pubmed/11864945
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25340832
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/history/ozenoxacin.html | https://clinicaltrials.gov/ct2/show/NCT02090764 | https://www.ncbi.nlm.nih.gov/pubmed/11864945
Ozenoxacin is an experimental quinolone antibiotic being developed for the treatment of impetigo and other dermatological bacterial infections. Ozenoxacin is active against some bacteria that have developed resistance to currently used quinolone and fluoroquinolone antibiotics. In two phase 3 studies, Ozenoxacin cream, 1%, applied topically twice daily for 5 days vs. placebo, demonstrated superiority on both clinical and bacteriological endpoints, according to the release. Superior bacteriological cure of Ozenoxacin compared to placebo was demonstrated as early as day 4. In both adults and a pediatric population aged 2 months and older, Ozenoxacin treatment was reported to be safe and well tolerated.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3038508 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11864945 |
|||
Target ID: CHEMBL2311224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11864945 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | XEPI Approved UseXEPI™ is indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older Launch Date2017 |
|||
Curative | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy, 2 months of age and above Health Status: unhealthy Age Group: 2 months of age and above Sex: M+F Sources: |
Disc. AE: Rosacea, Seborrheic dermatitis... AEs leading to discontinuation/dose reduction: Rosacea (grade 1, 0.5%) Sources: Seborrheic dermatitis (grade 2, 0.5%) Skin tightness (grade 3, 0.5%) Eczema (grade 4, 0.5%) |
50 mg 1 times / day single, topical Highest studied dose Dose: 50 mg, 1 times / day Route: topical Route: single Dose: 50 mg, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Other AEs: Application site itching... Other AEs: Application site itching (grade 1, 12.5%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Rosacea | grade 1, 0.5% Disc. AE |
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy, 2 months of age and above Health Status: unhealthy Age Group: 2 months of age and above Sex: M+F Sources: |
Seborrheic dermatitis | grade 2, 0.5% Disc. AE |
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy, 2 months of age and above Health Status: unhealthy Age Group: 2 months of age and above Sex: M+F Sources: |
Skin tightness | grade 3, 0.5% Disc. AE |
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy, 2 months of age and above Health Status: unhealthy Age Group: 2 months of age and above Sex: M+F Sources: |
Eczema | grade 4, 0.5% Disc. AE |
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy, 2 months of age and above Health Status: unhealthy Age Group: 2 months of age and above Sex: M+F Sources: |
Application site itching | grade 1, 12.5% | 50 mg 1 times / day single, topical Highest studied dose Dose: 50 mg, 1 times / day Route: topical Route: single Dose: 50 mg, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes [IC50 >=100 uM] | ||||
yes [IC50 >=100 uM] |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25340832
1% cream was applied topically on affected area of 1–100 cm^2 twice dally for 5 days
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11864945
In vitro development of resistance was carried out using a broth microdilution method by exposing bacteria to stepwise increasing concentrations of T-3912 (Ozenoxacin). Selection of drug-resistant derivatives was carried out by exposure of 5. aureus SA113 and P. ctcnes JCM6425 to stepwise increasing concentrations of T-3912. A series of microtitre wells containing two-fold serial dilutions of T-3912 was inoculated with a final concentration of 10^5 cfu/mL and then incubated for 24 h for S. aureus SA113 and for 48 h for P. acnes JCM6425. In the next step, the well with the highest T-3912 concentration still showing turbidity was used to inoculate a new series of microtitre tray. The procedure was repeated, and the MICs were determined for up to 28 passages.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:53 GMT 2025
by
admin
on
Mon Mar 31 18:21:53 GMT 2025
|
Record UNII |
V0LH498RFO
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
D06AX14
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
||
|
NDF-RT |
N0000175937
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
||
|
NCI_THESAURUS |
C795
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
V0LH498RFO
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
V0LH498RFO
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
DB12924
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
Ozenoxacin
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
100000172897
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
245765-41-7
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
5058
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
C90935
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
Ozenoxacin
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
HI-129
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
DTXSID00947446
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
m11943
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
1994739
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
9863827
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
8788
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR |
In vitro, ozenoxacin caused mild inhibition of CYP3A4 and CYP2C9 at high concentrations (?100 ?M).
|
||
|
METABOLIC ENZYME -> INHIBITOR |
In vitro, ozenoxacin caused mild inhibition of CYP3A4 and CYP2C9 at high concentrations (?100 ?M).
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |